# Biotech Daily Digest — 2025-09-07

**43 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 7 items
- Endpoints News: 7 items
- Fierce Biotech: 17 items
- MHRA – News: 2 items
- Regeneron Press Releases: 10 items


## Eli Lilly Press Releases

- **[Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers](https://investor.lilly.com/news-releases/news-release-details/lillys-olomorasib-receives-us-fdas-breakthrough-therapy)**  
  _Thu, 04 Sep 2025 06:45:00 -0400_  
  The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be presented at the IASLC 2025 World Conference on Lung Cancer   INDIANAPOLIS , Sept.

- **[Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial)**  
  _Tue, 26 Aug 2025 06:45:00 -0400_  
  In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an

- **[Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference](https://investor.lilly.com/news-releases/news-release-details/lilly-participate-morgan-stanley-23rd-annual-global-healthcare)**  
  _Mon, 25 Aug 2025 09:00:00 -0400_  
  INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23 rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman , M.D., Lilly chief medical

- **[Lilly to participate in Wells Fargo 20th Annual Healthcare Conference](https://investor.lilly.com/news-releases/news-release-details/lilly-participate-wells-fargo-20th-annual-healthcare-conference)**  
  _Fri, 22 Aug 2025 09:00:00 -0400_  
  INDIANAPOLIS , Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025 . Patrik Jonsson , executive vice president and president of Lilly International , will take part in a fireside chat at 9:30 a.m.,

- **[Anne White to Retire as Executive Vice President and President, Lilly Neuroscience](https://investor.lilly.com/news-releases/news-release-details/anne-white-retire-executive-vice-president-and-president-lilly)**  
  _Wed, 20 Aug 2025 09:00:00 -0400_  
  INDIANAPOLIS , Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025 .  She will continue to serve in her role and as

- **[Lilly launches "The Court Is Hers™" to help more girls get in the game](https://investor.lilly.com/news-releases/news-release-details/lilly-launches-court-herstm-help-more-girls-get-game)**  
  _Sat, 09 Aug 2025 15:00:00 -0400_  
  Through partnerships with the Indiana Fever and the YMCA of Greater Indianapolis, this citywide initiative helps expand access to youth basketball for girls across Indianapolis INDIANAPOLIS, Aug. 9, 2025 — Eli Lilly and Company, in partnerships with the Indiana Fever and the YMCA of Greater

- **[Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273)**  
  _Thu, 07 Aug 2025 06:25:00 -0400_  
  In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of


## Endpoints News

- **[#WCLC25: Summit reports full Phase 3 data from first group of Western lung cancer patients](https://endpoints.news/wclc25-summit-reports-full-phase-3-data-from-first-group-of-western-lung-cancer-patients/)**  
  _Sun, 07 Sep 2025 07:30:43 +0000_  
  Summit Therapeutics released a much-anticipated cut of data in North American and European lung cancer patients on Sunday, trumpeting a new analysis in which its drug ivonescimab, when added to chemotherapy, reduced the risk of ...

- **[BioNTech and DualityBio’s ADC hits in late-stage breast cancer trial in China](https://endpoints.news/biontech-and-dualitybios-adc-hits-in-late-stage-breast-cancer-trial-in-china/)**  
  _Fri, 05 Sep 2025 11:04:34 +0000_  
  BioNTech said its most advanced antibody-drug conjugate has succeeded in a Phase 3 China-based trial in hard-to-treat breast cancer patients. The win will raise expectations for an ongoing global late-phase trial of the drug.  ...

- **[Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves](https://endpoints.news/merck-kgaa-finds-its-next-r-exelixis-retools-management-team-as-medical-chief-leaves/)**  
  _Fri, 05 Sep 2025 11:00:32 +0000_  
  → Merck KGaA has selected David Weinreich as global R&D chief and CMO for the healthcare business sector. Weinreich’s experience with larger pharmas goes back to his days at Amgen as ...

- **[Hengrui does another US deal, this time in Cytokinetics' cardio arena](https://endpoints.news/hengrui-does-another-us-deal-this-time-in-cytokinetics-cardio-arena/)**  
  _Fri, 05 Sep 2025 08:01:47 +0000_  
  Jiangsu Hengrui Pharmaceuticals, China's leading drug developer and producer of one of the largest pipelines in the entire biopharma industry, has outlicensed another candidate to a US biotech.

 This time, Hengrui is teaming up with ...

- **[AstraZeneca ends manufacturing license at Indian plant as it exits the site](https://endpoints.news/astrazeneca-ends-manufacturing-license-at-indian-plant-as-it-exits-the-site/)**  
  _Thu, 04 Sep 2025 16:16:12 +0000_  
  AstraZeneca is terminating a manufacturing license at its factory in Bengaluru, India, after announcing its plans to sell the facility last year, a company spokesperson confirmed to Endpoints News.

 The manufacturing license at the site ...

- **[MindMed details Phase 2b LSD data in medical journal](https://endpoints.news/mindmed-details-phase-2b-lsd-data-in-medical-journal/)**  
  _Thu, 04 Sep 2025 15:00:19 +0000_  
  MindMed detailed promising Phase 2b results for its LSD treatment for generalized anxiety disorder as it presses on with three late-stage trials in the increasingly competitive field of psychedelic medicine.

 The company published data Thursday ...

- **[Exothera shutters; Lotte Biologics’ latest contract with an unnamed US client](https://endpoints.news/exothera-shutters-lotte-biologics-latest-contract-with-an-unnamed-us-client/)**  
  _Thu, 04 Sep 2025 14:19:31 +0000_  
  Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 Exothera has shut down due to the “increasingly challenging” CDMO landscape, the ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/daiichi-mercks-advanced-lung-cancer-adc-sees-48-response-registrational-trial" hreflang="en">Daiichi-Merck’s advanced lung cancer ADC sees 48% response rate in registrational trial</a>](https://www.fiercebiotech.com/biotech/daiichi-mercks-advanced-lung-cancer-adc-sees-48-response-registrational-trial)**  
  _Sep 5, 2025 12:01pm_  
  Partners Daiichi Sankyo and Merck & Co. are sharing phase 2 data for their investigational antibody-drug conjugate, findings the partners think will help score accelerated approval in pre-treated small cell lung cancer.

- **[<a href="https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival" hreflang="en">Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend</a>](https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival)**  
  _Sep 6, 2025 6:18pm_  
  Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations may be disappointed, although hopes for an approval remain alive thanks to newly calculated overall survival data from a…

- **[<a href="https://www.fiercebiotech.com/biotech/several-concerning-observations-fda-sheds-more-light-rejected-drugs" hreflang="en">'Several concerning observations': FDA sheds more light on reasons it rejected drugs</a>](https://www.fiercebiotech.com/biotech/several-concerning-observations-fda-sheds-more-light-rejected-drugs)**  
  _Sep 5, 2025 9:20am_  
  The FDA’s ongoing effort to establish a culture of “radical transparency” saw the agency publish another haul of complete response letters yesterday.

- **[<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-merck-kgaa-lands-new-rd-chief" hreflang="en">Chutes &amp; Ladders—Merck KGaA lands new R&amp;D chief</a>](https://www.fiercebiotech.com/biotech/chutes-ladders-merck-kgaa-lands-new-rd-chief)**  
  _Sep 4, 2025 4:37pm_  
  The German pharma giant has found a new pipeline leader in David Weinreich, M.D., who is joining the company as global head of R&D and chief medical officer for its healthcare unit. Weinreich, who will work out of Merck’s Massachusetts R&D site, was most recently an operating partner and senior advisor at Foresite Lab…

- **[<a href="https://www.fiercebiotech.com/biotech/biontechs-her2-adc-beats-roches-kadcyla-phase-3-breast-cancer-trial" hreflang="en">BioNTech's HER2 ADC beats Roche's Kadcyla in phase 3 breast cancer trial</a>](https://www.fiercebiotech.com/biotech/biontechs-her2-adc-beats-roches-kadcyla-phase-3-breast-cancer-trial)**  
  _Sep 5, 2025 7:16am_  
  BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Biologics to seek approval for the candidate in China.

- **[<a href="https://www.fiercebiotech.com/pharma/rfk-jr-lays-blame-pharma-industry-touts-mrna-vaccine-misinformation-heated-senate-hearing" hreflang="en">RFK Jr. blasts pharma industry, touts mRNA misinformation in heated Senate hearing</a>](https://www.fiercebiotech.com/pharma/rfk-jr-lays-blame-pharma-industry-touts-mrna-vaccine-misinformation-heated-senate-hearing)**  
  _Sep 4, 2025 3:06pm_  
  During a tense and at times incendiary Senate hearing Thursday, Robert F. Kennedy Jr. blamed the pharmaceutical industry and fell back on vaccine misinformation as he sought to defend the tumult that has consumed the federal health apparatus during his first eight months as the nation’s Health and Human Services secre…

- **[<a href="https://www.fiercebiotech.com/biotech/fda-announces-plan-publish-drug-rejection-letters-real-time-releases-new-batch-including" hreflang="en">FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub</a>](https://www.fiercebiotech.com/biotech/fda-announces-plan-publish-drug-rejection-letters-real-time-releases-new-batch-including)**  
  _Sep 4, 2025 12:42pm_  
  The Food and Drug Administration today announced a plan to publicly release complete response letters at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical transparency.”

- **[<a href="https://www.fiercebiotech.com/medtech/galvanize-therapeutics-nets-100m-and-new-ceo-bring-pulsed-field-ablation-lung-cancer" hreflang="en">Galvanize Therapeutics nets $100M, and a new CEO, to bring pulsed field ablation to lung cancer</a>](https://www.fiercebiotech.com/medtech/galvanize-therapeutics-nets-100m-and-new-ceo-bring-pulsed-field-ablation-lung-cancer)**  
  _Sep 4, 2025 12:47pm_  
  The company has named its chairman, Doug Godshall, as CEO amid a $100 million series C venture capital fundraising.

- **[<a href="https://www.fiercebiotech.com/medtech/quest-diagnostics-launches-new-pharmacogenomics-testing-program" hreflang="en">Quest Diagnostics launches new pharmacogenomics testing program</a>](https://www.fiercebiotech.com/medtech/quest-diagnostics-launches-new-pharmacogenomics-testing-program)**  
  _Sep 4, 2025 11:43am_  
  Quest said its test will span drugs used across psychiatry, neurology, cardiology, oncology, rheumatology and pain management, as well as for transplant recipients.

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025" hreflang="en">Fierce Biotech Layoff Tracker 2025: AC Immune cuts 30% of staff; Novartis plans 58 layoffs</a>](https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025)**  
  _Dec 23, 2024 11:52am_  
  As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

- **[<a href="https://www.fiercebiotech.com/biotech/enveda-harvests-another-150m-advance-nature-inspired-drugs" hreflang="en">Enveda harvests another $150M to advance nature-inspired drugs</a>](https://www.fiercebiotech.com/biotech/enveda-harvests-another-150m-advance-nature-inspired-drugs)**  
  _Sep 4, 2025 9:15am_  
  Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding beyond $500 million, positions the biotech to advance a crop of programs into the clinic behind its phase 1b eczema prospect.

- **[<a href="https://www.fiercebiotech.com/cro/australian-biotech-filamon-partners-pi-health-anti-inflammatory-cancer-trial" hreflang="en">Australian biotech Filamon partners with Pi Health for anti-inflammatory cancer trial</a>](https://www.fiercebiotech.com/cro/australian-biotech-filamon-partners-pi-health-anti-inflammatory-cancer-trial)**  
  _Sep 3, 2025 2:11pm_  
  Global CRO Pi Health has pulled a new partnership out of the oven. Building on a growing presence Down Under, Pi Health will provide CRO services and a clinical trial software platform to Australian biotech Filamon.

- **[<a href="https://www.fiercebiotech.com/regulatory/medical-and-public-health-leaders-demand-rfk-jrs-resignation-hhs-employees-also-join" hreflang="en">Medical and public health leaders demand RFK Jr.'s resignation, as growing number of HHS employees also join the call</a>](https://www.fiercebiotech.com/regulatory/medical-and-public-health-leaders-demand-rfk-jrs-resignation-hhs-employees-also-join)**  
  _Sep 4, 2025 7:28am_  
  The public statement from more than 20 organizations comes as about 1,000 former and current HHS staffers are also calling for RFK Jr.'s resignation, warning that he "continues to endanger the nation’s health."

- **[<a href="https://www.fiercebiotech.com/biotech/rash-selling-sanofi-shares-slump-phase-3-eczema-win-fails-soothe-market-fears" hreflang="en">Sanofi phase 3 eczema win falls short of analyst expectations </a>](https://www.fiercebiotech.com/biotech/rash-selling-sanofi-shares-slump-phase-3-eczema-win-fails-soothe-market-fears)**  
  _Sep 4, 2025 4:46am_  
  A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% in Paris.

- **[<a href="https://www.fiercebiotech.com/biotech/amgens-stomach-cancer-candidate-takes-turn-attenuated-os-benefits-final-phase-3-analysis" hreflang="en">Amgen-Zai stomach cancer candidate takes a turn with 'attenuated' OS benefits at final phase 3 analysis </a>](https://www.fiercebiotech.com/biotech/amgens-stomach-cancer-candidate-takes-turn-attenuated-os-benefits-final-phase-3-analysis)**  
  _Sep 3, 2025 3:46pm_  
  An interim analysis reported in June showed that Amgen's Zai Labs-partnered bemarituzumab made improvements in overall survival, but the final analysis tells a different story.

- **[<a href="https://www.fiercebiotech.com/biotech/gileads-kite-pharma-erodes-23b-shelf-cell-therapy-deal-shoreline-biosciences" hreflang="en">Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline</a>](https://www.fiercebiotech.com/biotech/gileads-kite-pharma-erodes-23b-shelf-cell-therapy-deal-shoreline-biosciences)**  
  _Sep 3, 2025 3:20pm_  
  Gilead Sciences' Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies that was valued at more than $2.3 billion.

- **[<a href="https://www.fiercebiotech.com/medtech/illumina-begins-rolling-out-protein-prep-platform-ahead-somalogic-buy" hreflang="en">Illumina begins rolling out protein prep platform ahead of SomaLogic buy</a>](https://www.fiercebiotech.com/medtech/illumina-begins-rolling-out-protein-prep-platform-ahead-somalogic-buy)**  
  _Sep 3, 2025 2:12pm_  
  The ink isn't dry on Illumina's $425 million deal to acquire SomaLogic, but the two companies are moving forward with the proteomics platform they've been developing together for years.


## MHRA – News

- **[Guidance: Medical devices: Standardised format for the post market surveillance report](https://www.gov.uk/government/publications/medical-devices-standardised-format-for-the-post-market-surveillance-report)**  
  _2025-09-05T14:14:52Z_  
  Information and recommendations for manufacturers on the preparation and presentation of a post market surveillance report (PMSR).

- **[Designated standards prioritisation](https://www.gov.uk/government/calls-for-evidence/designated-standards-prioritisation)**  
  _2025-09-04T23:01:01Z_  
  The MHRA invite feedback on the use of designated standards for medical devices and in vitro diagnostic (IVD) devices to help shape future initiatives.


## Regeneron Press Releases

- **[Regeneron Announces Updated Presentation Time for Upcoming Investor Conference](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-updated-presentation-time-upcoming-investor)**  
  _Thu, 04 Sep 2025 16:05:00 -0400_  
  TARRYTOWN, N.Y. , Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals , Inc. (NASDAQ:  REGN ) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025.

- **[Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-phase-3-trial-generalized)**  
  _Tue, 26 Aug 2025 07:00:00 -0400_  
  Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for

- **[EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-applications-expanded-us)**  
  _Wed, 20 Aug 2025 11:19:00 -0400_  
  TARRYTOWN, N.Y. , Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD ® (aflibercept) Injection 8 mg regulatory

- **[Regeneron Announces Investor Conference Presentations](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-21)**  
  _Thu, 07 Aug 2025 16:05:00 -0400_  
  TARRYTOWN, N.Y. , Aug. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 2025 2025 Wells Fargo Healthcare Conference at 9:30 a.m.

- **[Regeneron Reports Second Quarter 2025 Financial and Operating Results](https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2025-financial-and-operating)**  
  _Fri, 01 Aug 2025 06:30:00 -0400_  
  Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024 Dupixent ® global net sales   (recorded by Sanofi) increased 22% to $4.34 billion   EYLEA HD ® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA ® U.S.

- **[Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2025-winners-regeneron-prize-creative)**  
  _Thu, 24 Jul 2025 07:30:00 -0400_  
  TARRYTOWN, N.Y. , July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career

- **[Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma](https://investor.regeneron.com/news-releases/news-release-details/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval)**  
  _Wed, 02 Jul 2025 11:00:00 -0400_  
  TARRYTOWN, N.Y. , July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple

- **[Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025](https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2025-financial-and-operating)**  
  _Thu, 26 Jun 2025 16:05:00 -0400_  
  TARRYTOWN, N.Y. , June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025 , before the U.S. financial markets open.

- **[Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-first-its-kind-donation-matching-program)**  
  _Tue, 24 Jun 2025 07:30:00 -0400_  
  Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications TARRYTOWN, N.Y. , June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the launch of a pioneering matching program for donations to Good

- **[Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)](https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-only-targeted-medicine-treat)**  
  _Fri, 20 Jun 2025 01:00:00 -0400_  
  Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S.
